Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

This open‐label, single‐dose, randomized, parallel‐group, 2‐arm phase 1 bioequivalence (BE) study assessed the pharmacokinetics (PK), safety, and tolerability of PF‐06410293 (ADL‐PF), an adalimumab (ADL) biosimilar, following administration by prefilled pen (PFP) or prefilled syringe (PFS). A total...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Donna S., Alvarez, Daniel F., Bock, Amy E., Cronenberger, Carol L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518774/
https://www.ncbi.nlm.nih.gov/pubmed/33765358
http://dx.doi.org/10.1002/cpdd.939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518774/
https://www.ncbi.nlm.nih.gov/pubmed/33765358
http://dx.doi.org/10.1002/cpdd.939

Ejemplares similares